Citius pharmaceuticals, inc. reports fiscal full year 2023 financial results and provides business update

Mino-lok® pivotal phase 3 trial enrollment completed; topline data expected 2q 2024 lymphir™ bla resubmission on track for early 2024 cranford, n.j. , jan. 2, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended september 30, 2023.
CTXR Ratings Summary
CTXR Quant Ranking